ClinicalTrials.Veeva

Menu
N

New England Retina Consultants | Retina Research Institute

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KSI-301
Tarcocimab
APL-2
AVD-104
methotrexate
EYP-1901
CU06-1004
Triamcinolone Acetonide
ANX007
ADX-2191

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 16 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad
Locations recently updated

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

Active, not recruiting
Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: AXT107 Mid Dose
Drug: AXT107 High Dose

Trial sponsors

Kodiak Sciences logo
4
Aldeyra Therapeutics logo
A
A
A
A
C
C
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems